Emerging monoclonal antibody therapies for malignant gliomas (Q36764016)

16 August 2017

1 reference

title

Emerging monoclonal antibody therapies for malignant gliomas (English)

1 reference

16 August 2017

1 reference

David E Gerber

1

1 reference

PubMed ID

17371196

16 August 2017

John Laterra

series ordinal

2

1 reference

PubMed ID

17371196

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

1 reference

16 August 2017

16

1 reference

16 August 2017

4

1 reference

16 August 2017

477-494

1 reference

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Monoclonal antibodies for brain tumour treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Designing antibodies for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Human antiglioma monoclonal antibodies from patients with astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Antibodies and their fragments as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

(131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Vascular gene expression in nonneoplastic and malignant brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Clinical impact and functional aspects of tenascin-C expression during glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Molecular biology of epidermal growth factor receptor inhibition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Classification of glioblastoma multiforme in adults by molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Human glioma-specific antigens detected by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

EGFRvIII as a promising target for antibody-based brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

VEGF inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Progress report on the potential of angiogenesis inhibitors for neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Targeted radiotherapy of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

Intraventricular immunotoxin therapy for leptomeningeal neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.477

10.1517/13543784.16.4.477

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17371196